vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and ROGERS CORP (ROG). Click either name above to swap in a different company.
ROGERS CORP is the larger business by last-quarter revenue ($200.5M vs $168.4M, roughly 1.2× Esperion Therapeutics, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 5.2%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs -3.3%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
Rogers Corporation is a specialty engineered materials company headquartered in Chandler, Arizona.
ESPR vs ROG — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $200.5M |
| Net Profit | — | $4.5M |
| Gross Margin | — | 32.2% |
| Operating Margin | 50.6% | — |
| Net Margin | — | 2.2% |
| Revenue YoY | 143.7% | 5.2% |
| Net Profit YoY | — | 421.4% |
| EPS (diluted) | $0.32 | $0.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $200.5M | ||
| Q4 25 | $168.4M | $201.5M | ||
| Q3 25 | $87.3M | $216.0M | ||
| Q2 25 | $82.4M | $202.8M | ||
| Q1 25 | $65.0M | $190.5M | ||
| Q4 24 | $69.1M | $192.2M | ||
| Q3 24 | $51.6M | $210.3M | ||
| Q2 24 | $73.8M | $214.2M |
| Q1 26 | — | $4.5M | ||
| Q4 25 | — | $4.6M | ||
| Q3 25 | $-31.3M | $8.6M | ||
| Q2 25 | $-12.7M | $-73.6M | ||
| Q1 25 | $-40.5M | $-1.4M | ||
| Q4 24 | — | $-500.0K | ||
| Q3 24 | $-29.5M | $10.7M | ||
| Q2 24 | $-61.9M | $8.1M |
| Q1 26 | — | 32.2% | ||
| Q4 25 | — | 31.5% | ||
| Q3 25 | — | 33.5% | ||
| Q2 25 | — | 31.6% | ||
| Q1 25 | — | 29.9% | ||
| Q4 24 | — | 32.1% | ||
| Q3 24 | — | 35.2% | ||
| Q2 24 | — | 34.1% |
| Q1 26 | — | — | ||
| Q4 25 | 50.6% | 3.5% | ||
| Q3 25 | -11.4% | 7.3% | ||
| Q2 25 | 8.6% | -33.3% | ||
| Q1 25 | -34.0% | -0.2% | ||
| Q4 24 | -6.4% | -6.6% | ||
| Q3 24 | -31.0% | 6.9% | ||
| Q2 24 | 3.5% | 5.3% |
| Q1 26 | — | 2.2% | ||
| Q4 25 | — | 2.3% | ||
| Q3 25 | -35.9% | 4.0% | ||
| Q2 25 | -15.4% | -36.3% | ||
| Q1 25 | -62.2% | -0.7% | ||
| Q4 24 | — | -0.3% | ||
| Q3 24 | -57.2% | 5.1% | ||
| Q2 24 | -83.9% | 3.8% |
| Q1 26 | — | $0.25 | ||
| Q4 25 | $0.32 | $0.20 | ||
| Q3 25 | $-0.16 | $0.48 | ||
| Q2 25 | $-0.06 | $-4.00 | ||
| Q1 25 | $-0.21 | $-0.08 | ||
| Q4 24 | $-0.14 | $-0.04 | ||
| Q3 24 | $-0.15 | $0.58 | ||
| Q2 24 | $-0.33 | $0.44 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | $195.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-302.0M | $1.2B |
| Total Assets | $465.9M | $1.4B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $195.8M | ||
| Q4 25 | $167.9M | $197.0M | ||
| Q3 25 | $92.4M | $167.8M | ||
| Q2 25 | $86.1M | $157.2M | ||
| Q1 25 | $114.6M | $175.6M | ||
| Q4 24 | $144.8M | $159.8M | ||
| Q3 24 | $144.7M | $146.4M | ||
| Q2 24 | $189.3M | $119.9M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $-302.0M | $1.2B | ||
| Q3 25 | $-451.4M | $1.2B | ||
| Q2 25 | $-433.5M | $1.2B | ||
| Q1 25 | $-426.2M | $1.3B | ||
| Q4 24 | $-388.7M | $1.3B | ||
| Q3 24 | $-370.2M | $1.3B | ||
| Q2 24 | $-344.2M | $1.3B |
| Q1 26 | — | $1.4B | ||
| Q4 25 | $465.9M | $1.4B | ||
| Q3 25 | $364.0M | $1.4B | ||
| Q2 25 | $347.1M | $1.5B | ||
| Q1 25 | $324.0M | $1.5B | ||
| Q4 24 | $343.8M | $1.5B | ||
| Q3 24 | $314.1M | $1.5B | ||
| Q2 24 | $352.3M | $1.5B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | $5.8M |
| Free Cash FlowOCF − Capex | — | $1.1M |
| FCF MarginFCF / Revenue | — | 0.5% |
| Capex IntensityCapex / Revenue | 0.0% | 2.3% |
| Cash ConversionOCF / Net Profit | — | 1.29× |
| TTM Free Cash FlowTrailing 4 quarters | — | $70.1M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $5.8M | ||
| Q4 25 | $45.2M | $46.9M | ||
| Q3 25 | $-4.3M | $28.9M | ||
| Q2 25 | $-31.4M | $13.7M | ||
| Q1 25 | $-22.6M | $11.7M | ||
| Q4 24 | $-35.0M | $33.7M | ||
| Q3 24 | $-35.3M | $42.4M | ||
| Q2 24 | $-7.2M | $22.9M |
| Q1 26 | — | $1.1M | ||
| Q4 25 | — | $42.2M | ||
| Q3 25 | — | $21.2M | ||
| Q2 25 | — | $5.6M | ||
| Q1 25 | — | $2.1M | ||
| Q4 24 | — | $18.3M | ||
| Q3 24 | $-35.5M | $25.2M | ||
| Q2 24 | $-7.3M | $8.8M |
| Q1 26 | — | 0.5% | ||
| Q4 25 | — | 20.9% | ||
| Q3 25 | — | 9.8% | ||
| Q2 25 | — | 2.8% | ||
| Q1 25 | — | 1.1% | ||
| Q4 24 | — | 9.5% | ||
| Q3 24 | -68.7% | 12.0% | ||
| Q2 24 | -9.9% | 4.1% |
| Q1 26 | — | 2.3% | ||
| Q4 25 | 0.0% | 2.3% | ||
| Q3 25 | 0.0% | 3.6% | ||
| Q2 25 | 0.0% | 4.0% | ||
| Q1 25 | 0.0% | 5.0% | ||
| Q4 24 | 0.0% | 8.0% | ||
| Q3 24 | 0.3% | 8.2% | ||
| Q2 24 | 0.1% | 6.6% |
| Q1 26 | — | 1.29× | ||
| Q4 25 | — | 10.20× | ||
| Q3 25 | — | 3.36× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 3.96× | ||
| Q2 24 | — | 2.83× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
ROG
Segment breakdown not available.
